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The Duffy blood group system: a review
    G.M. Meny
Duffy was the fi rst blood group mapped to an autosome (chromo-
some 1) using cytogenetic studies. Duffy antigens are located on 
a glycoprotein that can be found on erythrocytes and other cells 
throughout the body. Fya and Fyb are products of their respective 
alleles (FY*A, FY*B). Fyx, characterized by weak Fyb expression, is 
a result of an additional mutation in FY*B. The Fy(a–b–) pheno-
type, most commonly found in Blacks, occurs primarily as a result 
of a GATA promoter region mutation upstream of the FY allele. 
This mutation prevents expression of Duffy glycoprotein on eryth-
rocytes only, while permitting expression on nonerythroid cells. 
Other antigens include Fy3, Fy5, and Fy6. Antibodies to Duffy 
antigens are usually clinically signifi cant and have been reported 
to cause hemolytic disease of the fetus and newborn. This review 
provides a general overview of the Duffy blood group system, in-
cluding the role of the Duffy glycoprotein as a chemokine receptor 
(Duffy antigen receptor for chemokines) and in malarial infection. 
Immunohematology 2010;26:51–56.
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History
The initial description related to the Duffy blood group system was published in 1950 when anti-Fya was observed during an investigation of a hemolytic 
transfusion reaction.1,2 The antibody was described in a 
43-year-old group O, D– individual with hemophilia who 
received a 3-unit transfusion for treatment of an episode 
of spontaneous bruising and bleeding. The transfusions 
were followed by rigors. Jaundice developed the day after 
transfusion. Investigation revealed an antibody that was 
detected only by the IAT and was named anti-Duffy (anti-
Fya) after the patient. An Fya phenotype frequency of 64.9 
percent was calculated, and gene frequencies for both Fya 
and the hypothetical Fyb were described.
 One year later, anti-Fyb was discovered by Ikin et al.3 
in a patient 2 days after the birth of her third child. None 
of the children were noted to show signs of HDN. Antibody 
investigations demonstrated that stronger reactions were 
observed when the antibody was tested in the presence of 
albumin than of saline and at 37°C than at room tempera-
ture. Confi rmation of a previously calculated Fyb phenotype 
frequency was noted. Of interest, the authors speculated on 
the possibility of a rare third allele, which would react with 
neither antibody.
 Duffy was the fi rst blood group locus to be assigned to an 
autosome (a nonsex chromosome). Investigators performed 
linkage analysis between serologic blood typing results and 
cytogenetic studies on four families, one of which was a 
three-generation family.4 The Duffy locus segregated with 
the uncoiler (Un) locus on chromosome 1 in three family 
studies and an inversion of chromosome 1 in one family 
study. The Un locus causes chromosome 1 to have an un-
usual lengthy appearance when viewed in metaphase. De-
scribing a family with an inversion break point provided 
additional evidence for assigning the Duffy locus to chro-
mosome 1.
Genetics and Inheritance
 Both FY and RH gene loci reside on chromosome 1. 
However, the FY locus is located on the long arm at posi-
tion 1q22→ q23, whereas RH resides on the short arm.5 Fya 
and Fyb are antithetical antigens produced by codominant 
alleles, FYA and FYB. Four phenotypes are defi ned by the 
corresponding antibodies, anti-Fya and anti-Fyb (see Table 
1). The Duffy system antigens are listed in Table 2. 
  The Fy(a–b–) phenotype is the major phenotype 
in Blacks, but is very rarely found in Caucasians. The phe-
notype found in Blacks is characterized by the presence of 
Fyb antigen on nonerythroid cells, but an absence of the Fyb 
antigen on RBCs.8 A mutation in the erythroid promoter 
GATA-1 binding motif explains why Fy(a–b–) individuals 
do not make anti-Fyb (see Molecular section). The Fy(a–b–) 
phenotype found in Caucasians is characterized by a lack of 
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Table 1. Duffy phenotypes, prevalence, and inherited alleles
Red cell
phenotype Caucasians Blacks Allele
Fy(a+b–) 20† 10† FY*01/FY*01 or 
FY*A/FY*A
Fy(a–b+) 32 20 FY*02/FY*02 or 
FY*B/FY*B
Fy(a+b+) 48 3 FY*A/FY*B
Fy(a–b–) Very rare 67 FY*/N.01–05, 
FY*/N.01–02‡
†Present in 70–90% of some Asian populations.
‡Nomenclature pending approval by the ISBT Working Party on 
Terminology for Red Cell Surface Antigens 
Table modifi ed from Daniels.6,7
Prevalence %
Table 2. Duffy antigens7
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delayed hemolytic transfusion reactions.17,22,23 Of interest, 
Vengelen-Tyler17 noted that anti-Fy3 developed after anti-
Fya in individuals receiving multiple RBC transfusions for 
treatment of sickle cell disease, and Olteanu et al.22 report-
ed a case of an acute hemolytic transfusion reaction caused 
solely by anti-Fy3 in an 8-year-old Black individual treated 
for repair of a femoral neck fracture.
 The only example of anti-Fy4 was described by Behzad 
et al.24 in a 12-year-old patient with sickle cell disease. This 
antibody appeared to react with Fy(a–b–), some Fy(a+b–) 
or Fy(a–b+), but no Fy(a+b+) RBCs. However, the existence 
of this antibody is in doubt owing to the lack of consistent 
test results between laboratories and sample instability on 
storage and shipment.
 Colledge et al.25 reported the first example of anti-Fy5 in 
an 11-year-old Fy(a–b–) Black individual who died of acute 
leukemia shortly after the antibody was discovered. Like 
anti-Fy3, anti-Fy5 reacted with enzyme-treated Fy(a+) or 
Fy(b+) RBCs. No reactivity was seen with Fy(a–b–) RBCs 
from Black individuals, or Rhnull cells with normal expres-
sion of Fya and Fyb antigens. One Fy(a–b–) RBC sample 
from a Caucasian individual was positive. Anti-Fy5 is re-
ported to cause delayed hemolytic transfusion reactions in 
patients with sickle cell disease who develop this antibody 
in conjunction with other blood group antibodies such as 
anti-Fya,17,26 and anti-K, -E, and -C.27
 No human anti-Fy6 has been identified. Monoclonal 
antibodies have been raised against Fy6 epitopes, as well as 
other Duffy blood group epitopes.28–30
Biochemistry
 The Duffy protein is composed of 336 amino acids. The 
numbering of amino acids (and nucleotides) has varied be-
cause two kinds of Duffy mRNA have been described: a less 
abundant form, that was the first to be discovered and cloned, 
encodes a protein of 338 amino acids whereas the more abun-
dant form encodes a protein of 336 amino acids and is the 
form that is represented in Figure 1.31,32 The Duffy protein is 
likely organized in the RBC membrane as an N-glycosylated 
protein that spans the membrane seven times (Fig. 1). Fya and 
Fyb differ by a single amino acid change at position 42 on the 
extracellular domain, with glycine resulting in Fya expression 
and aspartic acid resulting in Fyb expression.5,33 Both Fya and 
Fyb are sensitive to destruction when RBCs are treated with 
proteolytic enzymes such as papain or ficin. Trypsin treatment 
of RBCs does not result in destruction of Fya or Fyb.6
 The Fy(a–b+w) phenotype is associated with weak Fyb, 
Fy3, and Fy6 expression. This phenotype results from a mu-
tation in the FYB gene. The Fyx-associated mutation at posi-
tion 89 in the first cytoplasmic loop (Fig. 1) causes the Duffy 
protein to be unstable. This intracellular amino acid change 
causes a quantitative reduction in the amount of Duffy protein 
and, hence, a decreased amount of Fyb, Fy3, and Fy6 expres-
sion. The Arg89Cys change was found in 3.5 percent of Cau-
casians, but was not found in Blacks. Another mutation in the 
same area (Ala100Thr) does not alter Duffy expression.13,34
Duffy antigen expression in both erythroid and noneryth-
roid tissues. Different mutations are present in either the 
FYA or FYB gene, which prevent the Duffy protein from be-
ing formed. These individuals, interestingly, tend to form 
anti-Fy3.9–11
 Other alleles have been reported at the FY locus. The 
Fyx phenotype is associated with weak expression of Fyb, 
Fy3, and Fy5 antigens. Chown et al.12 first reported the Fyx 
gene and estimated the phenotype frequency in a Caucasian 
population was not more than 2 percent. It is now known 
that Fyx is caused by a point mutation in the FYB gene.13,14
Antibodies in the System
Anti-Fya and -Fyb
 Anti-Fya and -Fyb are found after transfusion or, less fre-
quently, as a result of pregnancy. They are rarely naturally 
occurring. Duffy antibodies are predominantly of the IgG1 
subclass, and 50 percent of anti-Fya examples bind comple-
ment. Anti-Fyb, identified about 20 times less frequently 
than anti-Fya, is usually present in sera with other alloan-
tibodies.15 Both antibodies cause immediate and delayed 
hemolytic transfusion reactions.16 When Fy(a–b–) Black 
individuals develop Duffy antibodies, they usually produce 
anti-Fya, which may be followed by anti-Fy3 or anti-Fy5.17,18 
Anti-Fyb is not produced.
 With regard to hemolytic disease of the fetus and new-
born (HDFN), anti-Fya was identified in 5.4 percent of 
atypical alloantibodies in a group of women receiving ob-
stetric care at a tertiary-care center. Of antibodies capable 
of causing HDFN, Kell blood group antibodies were identi-
fied most frequently (22%). In contrast, anti-Fyb was infre-
quently identified (0.2%). This compares with 0.5 percent 
to 3.1 percent of Duffy system antibodies detected in four 
other series of obstetric patients.19
 Hughes et al.20 reviewed the clinical outcome of 18 
pregnant women between 1959 and 2004 in whom anti-
Fya was the only alloantibody identified and the fetus was 
Fy(a+). Significant HDFN was identified in 2 of 18 (11%) 
pregnancies, resulting in exchange transfusion or intrauter-
ine transfusion. Maximum serum titers in these cases were 
32 and 128. Hydrops fetalis was not identified in any fetus, 
and no deaths attributable to HDFN were reported. A rare 
case of HDFN caused by anti-Fyb has been reported.21
Anti-Fy3, -Fy4, -Fy5, and -Fy6
 Anti-Fy3 was first described by Albrey et al.9 in a Cauca-
sian individual who was pregnant with her third child. The 
authors noted that this antibody’s reactivity “suggests that 
the Duffy system is more complicated than it seemed be-
fore.” Anti-Fy3 was unique in that it reacted with enzyme-
treated Fy(a+) or Fy(b+) RBCs, but failed to react with 
Fy(a–b–) RBCs from Black individuals. Clinically, the baby 
was reported to have mild HDFN (weakly positive DAT), 
but no treatment was required.
 Subsequent reports of anti-Fy3 have also been de-
scribed in Black individuals during investigation of acute or 
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Duffy blood group system
 The epitopes identified by monoclonal antibodies to 
Fy3 and Fy6 have been characterized. The Fy3 epitope is 
present on the third extracellular loop.35 Fy3, like Fy5, is 
resistant to destruction when RBCs are treated with prote-
olytic enzymes.6 The Fy6 epitope is located N-terminal to 
the Fya/Fyb site and is composed of multiple amino acids 
located between positions 19 and 25.28 Unlike Fy3, Fy6 is 
destroyed when RBCs are treated with proteolytic enzymes. 
Like Fya and Fyb, trypsin treatment of RBCs does not result 
in destruction of Fy6.6
Molecular
FYA and FYB
 The biochemical differences in Fya and Fyb antigens 
can be explained at a molecular level by a single nucleotide 
substitution. This substitution (G codes for Fya and A codes 
for Fyb) allowed DNA typing of the main Duffy antigens to 
be performed as the FY*A sequence correlated with a BanI 
restriction site.36
Fy(a–b–) Phenotype
 The Fy(a–b–) phenotype, detected in approximately 70 
percent of Black individuals, is identified very rarely in Cau-
casians. The molecular basis for this disparity is not only 
interesting from a scientific perspective, but has clinical im-
plications as well (see Clinical Significance). Erythroid-only 
suppression of Duffy antigen expression occurs because of a 
point mutation in the GATA-1 binding site in Black individ-
uals who have the Fy(a–b–) phenotype.8 GATA sequences 
are plentiful in the genome and function as promoters of 
many genes, including those involved in hematopoiesis.37 
The mutation present in the GATA promoter region of 
FY*B (–67, T to C) disrupts a binding site for the GATA-1 
erythroid transcription factor. A similar mutation has been 
identified in the GATA-1 promoter region of FY*A as well.38 
Duffy antigen expression is prevented on erythrocytes, but 
Fig. 1. The predicted Duffy glycoprotein seven-transmembrane 
domain structure. Amino acid changes responsible for the Fya/
Fyb polymorphism, the Fyx mutation, and Fy3 and Fy6 regions are 
indicated. N-glycosylation sites are shown as Y. Reprinted with 
permission from Westhoff and Reid.32
not on other cells.39 Thus, Duffy mRNA can be detected in 
nonerythroid cells such as lung, spleen, and colon of Black 
individuals with a mutated GATA box. However, bone mar-
row cells from the same individuals are negative for Duffy 
mRNA expression.
 The genetic mutations found in Fy(a–b–) Caucasians 
do not resemble those identified in Black individuals. Three 
individuals from multiple ethnic backgrounds (Cree Indi-
an, Lebanese Jewish, and Caucasian English) were found to 
have point mutations that encoded premature stop codons 
in either FY*A or FY*B. These mutated genes, if translated 
into proteins, result in unstable products that are quickly 
degraded. Thus, the Duffy proteins in Caucasian individu-
als are absent from all tissues, including RBCs.11
Clinical Significance
Duffy Glycoproteins and Chemokines
 Chemokines are proteins secreted by cells, such as im-
mune cells, which are used as communication signals to 
guide their interactions.40 Chemokine messages secreted 
from one cell are received and decoded by another cell via 
specific receptors, leading to various responses such as 
leukocyte chemotaxis and adhesion. Similar to the Duffy 
glycoprotein, many chemokine receptors have seven trans-
membrane domains. However, whereas other chemokine 
receptors specifically bind chemokines of a single class, the 
Duffy glycoprotein was found to bind a variety of chemok-
ines and is known as the Duffy antigen receptor for chemok-
ines (DARC).41,42
 The function of DARC is yet to be clearly defined. It has 
been suggested that DARC may permit the erythrocyte to 
serve as a chemokine “sink” or scavenger, thus limiting ac-
tivation of leukocytes in the systemic circulation. However, 
it is unclear how long chemokines remain bound to the cell 
surface or what happens to the chemokines at the end of 
the erythrocyte lifespan. In addition, it is unclear as to the 
importance of this function in inflammatory or infectious 
disease as Fy(a–b–) erythrocytes do not bind chemokines, 
although Fy(a–b+w) erythrocytes bind reduced amounts 
compared with Fy(a–b+) cells.34,41–43
DARC and Renal Disease
 If DARC serves as a scavenger or chemokine sink as part 
of an effort to limit inflammation, what role could DARC 
play in modulating an immune response in renal disease 
and renal transplantation? Using an anti-Fy6 monoclo-
nal antibody, Liu et al.44 performed immunohistochemical 
studies of renal biopsies from children with renal disease 
to examine Duffy antigen expression. Renal cell DARC ex-
pression was found to be upregulated in multiple causes of 
renal cell injury, including HIV nephropathy and hemolytic 
uremic syndrome. The authors speculate that the increased 
DARC expression may be the kidney’s attempt to bind and 
neutralize chemokines and control inflammation. They also 
 
IMMUNOHEMATOLOGY, Volume 26, Number 2, 201054
speculate that the high incidence of HIV nephropathy in 
Black individuals may thus be associated with the Fy(a–b–) 
phenotype.
 Other groups have attempted to find a correlation be-
tween Duffy antigen expression and renal graft survival, with 
mixed results. Akalin and Neylan45 found Duffy-negative 
graft recipients had lower allograft survival compared with 
recipients of other phenotypes and speculated that a loss 
of ability to bind chemokines leads DARC-negative recipi-
ents to be more vulnerable to poor graft function. Mange et 
al.46 did not confirm an association between a graft recipi-
ent with a null DARC phenotype and an increased incidence 
of acute renal allograft rejection or delayed graft function. 
One recent paper examined Duffy antigen mismatches be-
tween recipient and donor renal transplants and suggests a 
potential role for Duffy as a minor histocompatibility anti-
gen.47
DARC and Malaria
 In addition to serving as a chemokine receptor, the 
Duffy glycoprotein has been shown to be the erythroid re-
ceptor for Plasmodium vivax and Plasmodium knowlesi. 
Initially, P. knowlesi, a monkey malaria parasite, was used 
as an in vitro model to study human malaria. However, 
Miller et al.48 performed blood typing on 11 volunteers ex-
posed to P. vivax–infected mosquitoes and found that those 
who contracted malaria were Fy(a+) or Fy(b+), whereas 
those whose erythrocytes were resistant to parasitic inva-
sion were Fy(a–b–). Evidence has since shown that the P. 
vivax Duffy-binding protein (PvDbp) interacts with Duffy 
antigens on RBCs to permit RBC infection and that PvDbp 
may be a candidate for vaccine development.49
 P. vivax malaria is the most widely distributed malar-
ia in the world, with approximately 70 to 80 million cases 
occurring per year.50 Individuals with the Fy(a–b–) phe-
notype may have a selective advantage in that their RBCs 
are resistant to P. vivax invasion. This is evident in West 
Africa, where P. vivax malaria is absent and greater than 
95 percent of the population is Fy(a–b–). However, a few 
contradictions to a genetic adaptation hypothesis remain 
to be explained: the Fy(a–b–) phenotype is not common in 
Southeast Asia, another endemic area of P. vivax malaria, 
and P. vivax malaria infection is not lethal.5,50
The Clinical Value of Duffy Genotyping
 The use of Duffy DNA-based genotyping determina-
tions can be an adjunct to traditional phenotyping in clinical 
situations such as assessing for risk of HDFN and locating 
matched blood for alloimmunized patients. Goodrick et 
al.51 noted that although anti-Fya rarely causes significant 
HDFN, the ability to perform Duffy genotyping of fetal am-
niocytes can be of benefit when the father is heterozygous 
for FY*A. Regularly transfused patients, such as individuals 
with sickle cell disease, and any patient who makes one al-
loantibody are at a higher risk of forming multiple antibod-
ies.52 Duffy genotyping may be of assistance in providing 
matched blood by determining, for example, which Fy(a–
b–) patients carry the GATA-1 mutation in the promoter re-
gion of FY*B, as it is theorized that they can receive Fy(b+) 
blood without risk of forming anti-Fyb or anti-Fy3.53 Issues 
to consider in the use of Duffy genotyping include the need 
to detect silencing mutations, the potential for contamina-
tion of PCR-based assays, and the importance of correlating 
genotype results with phenotype results.
Summary
“Kell Kills, Duffy Dies, Lewis Lives”
Medical student Mantra related to alloantibody clinical sig-
nificance
 Many of the important discoveries in blood group se-
rology in the first half of the last century were descriptive in 
nature and focused on identification of RBC antigens and 
the clinical significance of their corresponding antibodies. 
The Duffy blood group system illustrates the progress made 
in elucidating the structure and function of blood group 
antigens. The Duffy glycoprotein acts as an erythrocyte re-
ceptor for certain malarial parasites and as a chemokine 
receptor (DARC). DARC may play a role in modulating the 
effects of certain renal diseases, as well as other disease 
states such as HIV54 or malignancy.55 Although significant 
progress has been made, much research remains to be com-
pleted to understand the structure and function of DARC.
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